docs/_posts/Ahmetemintek/2022-04-04-drug_action_treatment_mapper_en_3_0.md
docs/_posts/HashamUlHaq/2022-06-18-bert_token_classifier_drug_development_trials_en_3_0.md
docs/_posts/Meryem1425/2022-07-28-bert_sequence_classifier_drug_reviews_webmd_en_3_0.md
docs/_posts/gpirge/2022-06-28-ner_pathogen_en_3_0.md
docs/_posts/gpirge/2022-07-28-bert_token_classifier_disease_mentions_tweet_es_3_0.md
docs/_posts/gpirge/2022-07-28-bert_token_classifier_ner_pathogen_en_3_0.md
docs/_posts/gpirge/2022-07-29-bert_sequence_classifier_health_mandates_premise_tweet_en_3_0.md
docs/_posts/hsaglamlar/2022-06-30-ner_clinical_bert_ro_3_0.md
docs/_posts/hsaglamlar/2022-07-01-ner_clinical_ro_3_0.md
docs/_posts/josejuanmartinez/2022-04-05-re_zeroshot_biobert_en_3_0.md
docs/_posts/josejuanmartinez/2022-04-13-ner_deid_generic_pt_3_0.md
docs/_posts/josejuanmartinez/2022-04-13-ner_deid_subentity_pt_3_0.md
docs/_posts/josejuanmartinez/2022-04-14-clinical_deidentification_pt_3_0.md
docs/_posts/josejuanmartinez/2022-08-03-finance_sequence_classifier_augmented_esg_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-03-finance_sequence_classifier_esg_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-03-finance_sequence_classifier_news_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-03-finner_sec_conll_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-03-legner_cuad_silver_en_3_2.md
docs/_posts/luca-martial/2022-06-22-ner_clinical_trials_abstracts_en_3_0.md
docs/_posts/luca-martial/2022-06-29-bert_token_classifier_ner_clinical_trials_abstracts_en_3_0.md
docs/_posts/murat-gunay/2022-05-10-ner_biomedical_bc2gm_en_3_0.md
docs/_posts/murat-gunay/2022-05-11-ner_biomedical_bc2gm_en_2_4.md
docs/_posts/murat-gunay/2022-06-27-ner_deid_subentity_bert_ro_3_0.md
docs/_posts/murat-gunay/2022-06-27-ner_deid_subentity_ro_3_0.md
docs/_posts/murat-gunay/2022-07-06-ner_deid_generic_bert_ro_3_0.md
docs/_posts/murat-gunay/2022-07-08-ner_deid_generic_ro_3_0.md
docs/_posts/Ahmetemintek/2022-04-04-drug_action_treatment_mapper_en_3_0.md
docs/_posts/HashamUlHaq/2022-06-18-bert_token_classifier_drug_development_trials_en_3_0.md
docs/_posts/Meryem1425/2022-07-28-bert_sequence_classifier_drug_reviews_webmd_en_3_0.md
docs/_posts/gpirge/2022-06-28-ner_pathogen_en_3_0.md
docs/_posts/gpirge/2022-07-28-bert_token_classifier_disease_mentions_tweet_es_3_0.md
docs/_posts/gpirge/2022-07-28-bert_token_classifier_ner_pathogen_en_3_0.md
docs/_posts/gpirge/2022-07-29-bert_sequence_classifier_health_mandates_premise_tweet_en_3_0.md
docs/_posts/hsaglamlar/2022-06-30-ner_clinical_bert_ro_3_0.md
docs/_posts/hsaglamlar/2022-07-01-ner_clinical_ro_3_0.md
docs/_posts/josejuanmartinez/2022-04-05-re_zeroshot_biobert_en_3_0.md
docs/_posts/josejuanmartinez/2022-04-13-ner_deid_generic_pt_3_0.md
docs/_posts/josejuanmartinez/2022-04-13-ner_deid_subentity_pt_3_0.md
docs/_posts/josejuanmartinez/2022-04-14-clinical_deidentification_pt_3_0.md
docs/_posts/josejuanmartinez/2022-08-03-finance_sequence_classifier_augmented_esg_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-03-finance_sequence_classifier_esg_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-03-finance_sequence_classifier_news_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-03-finner_sec_conll_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-03-legner_cuad_silver_en_3_2.md
docs/_posts/luca-martial/2022-06-22-ner_clinical_trials_abstracts_en_3_0.md
docs/_posts/luca-martial/2022-06-29-bert_token_classifier_ner_clinical_trials_abstracts_en_3_0.md
docs/_posts/murat-gunay/2022-05-10-ner_biomedical_bc2gm_en_3_0.md
docs/_posts/murat-gunay/2022-05-11-ner_biomedical_bc2gm_en_2_4.md
docs/_posts/murat-gunay/2022-06-27-ner_deid_subentity_bert_ro_3_0.md
docs/_posts/murat-gunay/2022-06-27-ner_deid_subentity_ro_3_0.md
docs/_posts/murat-gunay/2022-07-06-ner_deid_generic_bert_ro_3_0.md
docs/_posts/murat-gunay/2022-07-08-ner_deid_generic_ro_3_0.md
